1 Key Insights

2 Contact Dermatitis Overview at a Glance

3 Executive Summary of Contact Dermatitis (CD)

4 Disease Background and Overview: Contact Dermatitis (CD)

4.1 Types
4.1.1 Irritant Contact Dermatitis (ICD)
4.1.2 Allergic Contact Dermatitis (ACD)
4.1.3 Contact Urticaria
4.2 Causes
4.2.1 Metals
4.2.2 Fragrances
4.2.3 Antibacterial Ointments
4.2.4 Formaldehyde
4.2.5 Isothiazolinones
4.2.6 Cocamidopropyl Betaine
4.2.7 Paraphenylene-Diamine
4.3 Symptoms
4.4 Pathophysiology
4.5 Diagnosis

5 Algorithm for Diagnosis and Management of CD

6 Diagnostic Guidelines by American Academy of Allergy Asthma & Immunology (AAAAI)

6.1 Clinical Evaluation
6.2 Patch testing recommendations
6.3 Sources of exposure to clinically relevant allergens
6.4 Topical medicinal CD
6.5 Special populations
6.5.1 CD in children
6.5.2 Occupational CD

7 Diagnostic Guidelines by the British Association of Dermatologists (BAD)

7.1 Assessment and Investigation
7.2 Diagnostic Tests (Diagnosis)
7.2.1 Preparation of the patient
7.2.2 Patch testing
7.2.3 Timing of patch test readings
7.2.4 Reading and relevance of positive reactions
7.2.5 Photopatch testing
7.2.6 Open patch testing

8 Epidemiology and Patient Population: Key Findings

8.1 7MM 7MM Total Diagnosed Prevalent Population of Contact Dermatitis

9 Country Wise-Epidemiology of Contact Dermatitis

9.1 United States
9.1.1 Assumptions and Rationale
9.1.2 Total Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.1.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States
9.1.4 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.1.5 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.1.6 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.2 EU5 Countries
9.2.1 Assumptions and Rationale
9.3 Germany
9.3.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.3.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany
9.3.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.3.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.3.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.4 France
9.4.1 Total Diagnosed Prevalent Population of Contact Dermatitis in France
9.4.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France
9.4.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France
9.4.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France
9.4.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France
9.5 Italy
9.5.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.5.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy
9.5.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.5.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.5.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.6 Spain
9.6.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.6.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain
9.6.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.6.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.6.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.7 United Kingdom
9.7.1 Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.7.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom
9.7.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.7.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.7.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.8 Japan
9.8.1 Assumptions and Rationale
9.8.2 Total Diagnosed Prevalent Population of Contact Dermatitis in Japan
9.8.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan

10 Appendix

10.1 Bibliography
10.2 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables
Table 1: Summary of Contact Dermatitis, Market, Epidemiology and Key Events (2017-2030)
Table 2: Classical clinical forms of CD
Table 3: Features that distinguishes between Irritant and Allergic Contact Dermatitis
Table 4: Exogenous and endogenous factors affecting clinical characteristics of CD
Table 5: The most important non-eczematous symptoms of contact allergic reactions
Table 6: Differential Diagnosis of Contact Dermatitis
Table 7: Scoring of patch test reactions according to the International Contact Dermatitis Research Group recommendations
Table 8: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7MM (2017-2030)
Table 9: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
Table 10: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the US (2017-2030)
Table 11: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
Table 12: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
Table 13: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
Table 14: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
Table 15: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Germany (2017-2030)
Table 16: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
Table 17: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
Table 18: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
Table 19: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
Table 20: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in France (2017-2030)
Table 21: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
Table 22: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
Table 23: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
Table 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
Table 25: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Italy (2017-2030)
Table 26: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
Table 27: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
Table 28: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
Table 29: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
Table 30: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Spain (2017-2030)
Table 31: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
Table 32: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
Table 33: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
Table 34: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
Table 35: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the UK (2017-2030)
Table 36: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
Table 37: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
Table 38: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
Table 39: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
Table 40: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Japan (2017-2030)
Table 41: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
Table 42: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
Table 43: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)

List of Figures
Figure 1: Pathophysiology of Allergic and Irritant CD
Figure 2: Algorithm for Diagnosis and Management of CD
Figure 3: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7MM (2017-2030)
Figure 4: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
Figure 5: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States (2017-2030)
Figure 6: Gender-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
Figure 7: Age-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
Figure 8: Type-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
Figure 9: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
Figure 10: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany (2017-2030)
Figure 11: Gender-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
Figure 12: Age-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
Figure 13: Type-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
Figure 14: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
Figure 15: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France (2017-2030)
Figure 16: Gender-specific Diagnosed Prevalent Population of CD in France (2017-2030)
Figure 17: Age-specific Diagnosed Prevalent Population of CD in France (2017-2030)
Figure 18: Type-specific Diagnosed Prevalent Population of CD in France (2017-2030)
Figure 19: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
Figure 20: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy (2017-2030)
Figure 21: Gender-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
Figure 22: Age-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
Figure 23: Type-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
Figure 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
Figure 25: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain (2017-2030)
Figure 26: Gender-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
Figure 27: Age-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
Figure 28: Type-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
Figure 29: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
Figure 30: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom (2017-2030)
Figure 31: Gender-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
Figure 32: Age-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
Figure 33: Type-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
Figure 34: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
Figure 35: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan (2017-2030)
Figure 36: Gender-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
Figure 37: Age-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
Figure 38: Type-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)